Advertisement
KRRO vs VIVS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRRO is a StrongBuy and VIVS is a Hold.
Momentum Indicator for KRRO turns positive, indicating new upward trend
KRRO saw its Momentum Indicator move above the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned positive. In 70 of the 80 cases, the stock moved higher in the following days. The odds of a move higher are at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for KRRO just turned positive on October 20, 2026. Looking at past instances where KRRO's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
KRRO moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for KRRO crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +6.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRRO advanced for three days, in 227 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 110 of 127 cases where KRRO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 87%.
Bearish Trend Analysis
The 10-day RSI Indicator for KRRO moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 46 cases where KRRO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 89%.
The 50-day moving average for KRRO moved below the 200-day moving average on October 15, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRRO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
KRRO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. KRRO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.104) is normal, around the industry mean (3.498). P/E Ratio (-1.493) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (69.444) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KRRO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
VIVS's RSI Oscillator climbs out of oversold territory
The RSI Indicator for VIVS moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 67 cases where VIVS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on VIVS as a result. In 71 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where VIVS advanced for three days, in 158 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
VIVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VIVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for VIVS entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.808) is normal, around the industry mean (3.498). P/E Ratio (-0.032) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (7.446) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. VIVS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VIVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
KRRO | VIVS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 45 | 28 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 64 Fair valued | 35 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 36 | 93 | |
P/E GROWTH RATING 1..100 | 79 | 98 | |
SEASONALITY SCORE 1..100 | 13 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VIVS's Valuation (35) in the Biotechnology industry is in the same range as KRRO (64) in the null industry. This means that VIVS’s stock grew similarly to KRRO’s over the last 12 months.
VIVS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as KRRO (100) in the null industry. This means that VIVS’s stock grew similarly to KRRO’s over the last 12 months.
VIVS's SMR Rating (100) in the Biotechnology industry is in the same range as KRRO (100) in the null industry. This means that VIVS’s stock grew similarly to KRRO’s over the last 12 months.
KRRO's Price Growth Rating (36) in the null industry is somewhat better than the same rating for VIVS (93) in the Biotechnology industry. This means that KRRO’s stock grew somewhat faster than VIVS’s over the last 12 months.
KRRO's P/E Growth Rating (79) in the null industry is in the same range as VIVS (98) in the Biotechnology industry. This means that KRRO’s stock grew similarly to VIVS’s over the last 12 months.
| KRRO | VIVS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 89% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 89% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 83% | N/A |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| Advances ODDS (%) | 2 days ago 86% | 3 days ago 78% |
| Declines ODDS (%) | about 1 month ago 90% | 9 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 87% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 87% | 1 day ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KRRO’s FA Score shows that 0 FA rating(s) are green while VIVS’s FA Score has 0 green FA rating(s).
- KRRO’s FA Score: 0 green, 5 red.
- VIVS’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KRRO’s TA Score shows that 5 TA indicator(s) are bullish while VIVS’s TA Score has 5 bullish TA indicator(s).
- KRRO’s TA Score: 5 bullish, 6 bearish.
- VIVS’s TA Score: 5 bullish, 2 bearish.
Price Growth
KRRO (@Biotechnology) experienced а -0.82% price change this week, while VIVS (@Biotechnology) price change was +1.58% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
KRRO is expected to report earnings on Mar 30, 2027.
VIVS is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KRRO and
Correlation & Price change
A.I.dvisor indicates that over the last year, KRRO has been loosely correlated with MGNX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if KRRO jumps, then MGNX could also see price increases.
| Ticker / NAME | Correlation To KRRO | 1D Price Change % | ||
|---|---|---|---|---|
| KRRO | 100% | -8.39% | ||
| MGNX - KRRO | 45% Loosely correlated | -4.13% | ||
| TRDA - KRRO | 43% Loosely correlated | +3.62% | ||
| RLAY - KRRO | 42% Loosely correlated | -1.10% | ||
| NRIX - KRRO | 37% Loosely correlated | +2.83% | ||
| ANRO - KRRO | 37% Loosely correlated | +8.88% | ||
More | ||||
VIVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, VIVS has been loosely correlated with DMRA. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VIVS jumps, then DMRA could also see price increases.
| Ticker / NAME | Correlation To VIVS | 1D Price Change % | ||
|---|---|---|---|---|
| VIVS | 100% | +19.47% | ||
| DMRA - VIVS | 38% Loosely correlated | -3.73% | ||
| ORMP - VIVS | 37% Loosely correlated | +4.03% | ||
| AEON - VIVS | 27% Poorly correlated | -4.41% | ||
| ACET - VIVS | 27% Poorly correlated | -0.33% | ||
| KRRO - VIVS | 26% Poorly correlated | -8.39% | ||
More | ||||